Company intelligence / Profile preview

CorreGene

Ownership: Private
Development stage: Phase 1

Overview

Two Investigator Initiated Trials launched. CRTE7A2 is in Phase I clinical trial targeting HPV16-positive advanced solid tumors including anal cancer. The company has reported improved success rates using its proprietary SMART-TCR technology to optimize affinity of therapeutic receptors.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: TCR-T cell therapiesSoluble TCR-fusion proteinsBispecific TCR therapiesGenetically engineered T cells
Industry: Biotech

Drug pipeline

14 assets

CRTE7A2-01

13 more assets in the full pipeline.

Request access →

Partnerships

Shenzhen Eureka Biotechnology Co., Ltd.

Beyond the preview

Go deeper on CorreGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorreGene.

Explore the full profile